Actinium Pharmaceuticals is focused on improving patient access and outcomes to hematopoietic cell transplantation and CAR-T cell therapy with its proprietary targeted conditioning technology. This technology is enabled by Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium's pipeline targets CD45 and CD33 in patients with a broad range of hematologic malignancies including AML, MDS and multiple myeloma.